Compare ARK Space & Defense Innovation ETF (ARKX) vs Incyte Corporation (INCY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Space & Defense Innovation ETF vs Incyte Corporation — how do they compare? ARK Space & Defense Innovation ETF trades at $31.76, while Incyte Corporation trades at $116.8 (market cap $23.32B). The key difference: Incyte Corporation is trading nearer its 52-week high, ARK Space & Defense Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKX | INCY | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $37.74 | $118.52 |
52-Week Low | $24.97 | $67.38 |
Market Cap | — | $23.32B |
Enterprise Value | — | $19.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARK Space Exploration & Innovation ETF (ARKX) trades at $32.05, down 0.82% today amid bearish technical signals. The ETF shows neutral oscillator readings but bearish moving averages, with key support at $32 and resistance at $33. Recent news highlights ARKX as a popular alternative to direct SpaceX investment, with the space economy reaching $500 billion in backlog according to 24/7 Wall Street (2026-07-06).
ARKX offers diversified exposure to the growing space sector without single-stock IPO risk. The ETF's higher volatility and expense ratio compared to traditional aerospace ETFs present both growth potential and increased risk. SpaceX's 8.31% weighting provides significant upside exposure but also concentration risk in a high-valuation name.
INCY trades at $116.71, down 1.53% on the day, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported robust revenue of $5.14 billion in 2025, with a net income margin of 26.71%, and recent news highlights regulatory approvals and portfolio expansion, including the acquisition of Vega Therapeutics.
The outlook is positive, driven by earnings beats, product pipeline advancements, and analyst consensus leaning buy. Key risks include execution of recent acquisitions and reliance on key products like Opzelura, but institutional sentiment remains strong with a consensus price target of $107.88.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Space & Defense Innovation ETF
ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.
Read more on ARKX →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
